Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M. Wise-Draper TM, et al. Among authors: palackdharry s. Clin Cancer Res. 2022 Apr 1;28(7):1345-1352. doi: 10.1158/1078-0432.CCR-21-3351. Clin Cancer Res. 2022. PMID: 35338369 Free PMC article. Clinical Trial.
Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma.
Wise-Draper T, Sendilnathan A, Palackdharry S, Pease N, Qualtieri J, Butler R, Sadraei NH, Morris JC, Patil Y, Wilson K, Mark J, Casper K, Takiar V, Lane A, Privette Vinnedge L. Wise-Draper T, et al. Among authors: palackdharry s. Transl Oncol. 2018 Feb;11(1):168-174. doi: 10.1016/j.tranon.2017.12.001. Epub 2017 Dec 28. Transl Oncol. 2018. PMID: 29289845 Free PMC article.
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM. Gulati S, et al. Among authors: palackdharry sm. Cancer. 2020 Jan 15;126(2):354-362. doi: 10.1002/cncr.32539. Epub 2019 Oct 18. Cancer. 2020. PMID: 31626727 Free PMC article. Clinical Trial.
PD1 blockade enhances K+ channel activity, Ca2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer.
Newton HS, Gawali VS, Chimote AA, Lehn MA, Palackdharry SM, Hinrichs BH, Jandarov R, Hildeman D, Janssen EM, Wise-Draper TM, Conforti L. Newton HS, et al. Among authors: palackdharry sm. J Immunother Cancer. 2020 Oct;8(2):e000844. doi: 10.1136/jitc-2020-000844. J Immunother Cancer. 2020. PMID: 33060146 Free PMC article.
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Wicker CA, Hunt BG, Krishnan S, Aziz K, Parajuli S, Palackdharry S, Elaban WR, Wise-Draper TM, Mills GB, Waltz SE, Takiar V. Wicker CA, et al. Among authors: palackdharry s. Cancer Lett. 2021 Apr 1;502:180-188. doi: 10.1016/j.canlet.2020.12.038. Epub 2021 Jan 12. Cancer Lett. 2021. PMID: 33450358 Free PMC article.
Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.
Leddon JL, Gulati S, Haque S, Allen C, Palackdharry S, Mathews M, Kurtzweil N, Riaz MK, Takiar V, Nagasaka M, Patil Y, Zender C, Tang A, Cervenka B, McGrath J, Korn WM, Hinrichs BH, Jandarov R, Harun N, Sukari A, Wise-Draper TM. Leddon JL, et al. Among authors: palackdharry s. Clin Cancer Res. 2022 Aug 15;28(16):3464-3472. doi: 10.1158/1078-0432.CCR-21-4554. Clin Cancer Res. 2022. PMID: 35653116 Free PMC article. Clinical Trial.
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M, Yaniv B, Palackdharry S, Lehn MA, Medvedovic M, Stone T, Gulati S, Karivedu V, Borchers M, Fuhrman B, Crago A, Curry J, Martinez-Outschoorn U, Takiar V, Wise-Draper TM. Crist M, et al. Among authors: palackdharry s. J Immunother Cancer. 2022 Nov;10(11):e005632. doi: 10.1136/jitc-2022-005632. J Immunother Cancer. 2022. PMID: 36328378 Free PMC article.
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial.
Gulati S, Crist M, Riaz MK, Takiar V, Lehn M, Monroe I, Palackdharry S, Kurtzweil N, Jandarov R, Harun N, Wise-Draper TM. Gulati S, et al. Among authors: palackdharry s. Clin Cancer Res. 2023 May 15;29(10):1906-1915. doi: 10.1158/1078-0432.CCR-22-3886. Clin Cancer Res. 2023. PMID: 36802410 Free PMC article. Clinical Trial.
11 results